EGFR and lung adenocarcinoma: However, the introduction of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) for patients with advanced-stage lung adenocarcinoma harboring activating EGFR mutations has changed the clinical course and survival rates of the patients with this type of cancer dramatically [2–4].